1. Home
  2. SNTI

SNTI

Senti Biosciences Inc.

Logo Senti Biosciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 12:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Founded: 2016 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 13.3M IPO Year: N/A
Target Price: $6.00 AVG Volume (30 days): 82.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.60 EPS Growth: N/A
52 Week Low/High: $0.27 - $1.22 Next Earning Date: 05-07-2024
Revenue: $2,561,000 Revenue Growth: -40.25%
Revenue Growth (this year): 254.47% Revenue Growth (next year): 169.66%

Share on Social Networks: